At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
Dronabinoldrug
Likely dose
Dronabinol 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
In Brief
A Phase 1 clinical trial evaluating Dronabinol for Brain Neoplasms and 2 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This study seeks to define the tolerability and safety associated with the administration of Dronabinol in the treatment of adults with nausea, vomiting and appetite loss in patients with primary gliomas who are undergoing chemotherapy treatment. The study will also describe the effect of Dronabinol on the quality of life in terms of nausea, vomiting and anorexia in this patient group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Neoplasms, Nausea, Vomiting
CountriesUnited States
CollaboratorsSolvay Pharmaceuticals
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionOct 2011
Study CompletionApr 2012
TodayJul 2026
First PostedApr 17, 2006
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 20.2 years ago
Interventions
Dronabinoldrug
Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy